CNS disorders such as depression, schizophrenia and Alzheimer’s disease, to name but a few, inflict a huge amount of suffering on patients, as well as sorrow and despair on their relatives. 

Hundreds of millions of people in the world suffer from CNS  disorders. In spite of therapeutic progress, unfortunately, we remain a long way from fully understanding these disorders. There are immense unmet needs, not only for medication, but also for entire solutions in which therapy and updated information about the disorders are crucial factors.

Unfortunately, public awareness and the resources spent on curing and alleviating CNS disorders are a long way from matching the severity and consequences of these disorders.

CNS disorders place an enormous economic burden on society because they reduce or eliminate the patient’s ability to work.

At Lundbeck, we have made it our ambition to be the company that makes the biggest difference worldwide in the treatment of patients suffering from CNS disorders. Assuming this responsibility is an enormous task, but it is also an incredible joy when we succeed in developing a new and innovative drug that benefits people worldwide.